SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Rivian Automotive, Inc. engages in the design, development, and manufacture of category-defining electric vehicles and accessories. It operates through following segments: Automotive, Software and Services. The company was founded by Robert J. Scaringe in June 2009 and is headquartered in Irvine, CA.

Rivian Automotive Inc - Ordinary Shares - Class A

Rivian Automotive Inc

Rivian is trending as it kicks off public deliveries for the R2 midsize SUV, with investors intensely debating whether the launch marks a pivotal shift toward profitability or just another "sell-the-news" event. The community is sharply divided between those cheering the R2's positive reviews and partnerships with firms like Uber, and those frustrated by continued cash burn, management's communication style, and the stock's persistent volatility.

Ocular Therapeutix, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapies for diseases and conditions of the eye. Its product pipeline includes Dextenza, OTX-TP, and OTX-TIC. The company was founded by Amarpreet S. Sawhney and Farhad Khosravi on September 12, 2006 and is headquartered in Bedford, MA.

Ocular Therapeutix Inc

Ocular Therapeutix is trending as investors debate the regulatory path for AXPAXLI, with community discussions heavily focused on the company's strategy for NDA submission based on single-trial data and potential M&A interest. While some shareholders remain optimistic about a buyout or partnership following strong clinical data, others are raising concerns over competitive legal threats, market volatility, and the timeline for upcoming investor presentations.

ARS Pharmaceuticals, Inc. is a biopharmaceutical company, which focuses on the development of a novel, potentially first-in-class product candidate, neffy, for the emergency treatment of Type I allergic reactions including anaphylaxis. Its product includes Epinephrine Nasal Spray. The company was founded by Richard Lowenthal, Robert Bell, and Sarina Tanimoto on August 5, 2015 and is headquartered in San Diego, CA.

ARS Pharmaceuticals Inc

SPRY is trending as investors digest news that the FDA has identified deficiencies in a competitors new drug application, effectively clearing a near-term runway for its needle-free epinephrine product. The community is actively discussing the potential for a major short squeeze, as the stock remains heavily shorted with a constrained float and growing global commercial momentum.

REGENXBIO, Inc. is a clinical-stage biotechnology company, which engages in the development, commercialization, and licensing of recombinant adeno-associated virus gene therapy. Its product candidates include the NAV Technology Platform, which consists of exclusive rights to novel adeno-associated viral vectors, and therapeutic programs such as RGX-314, RGX-202, RGX-121, RGX-111, RGX-181, and RGX-381. The company was founded by Kenneth T. Mills and James M. Wilson on July 16, 2008 and is headquartered in Rockville, MD.

Regenxbio Inc

Regenxbio is under intense market scrutiny following an FDA clinical hold placed on its RGX-111 and RGX-121 gene therapy programs due to a tumor found in a trial participant. The community is actively debating the implications for the February 8 PDUFA date for RGX-121, with many fearing a delay or rejection despite the company's efforts to advance its broader pipeline.

The TROLL token on the Solana network is a meme coin inspired by internet trolling culture, designed for entertainment and community engagement with no intrinsic value. Built on Solana’s blockchain, it leverages the network’s fast transactions and low fees to appeal to meme enthusiasts. Launched on decentralized exchanges, TROLL aims to foster a fun, community-driven ecosystem through social media, influencer partnerships, and viral marketing, embodying the playful spirit of online trolling.

Troll

Troll is gaining momentum as market participants increasingly highlight its status as an established meme with original IP rights and a growing community presence. Investors are actively drawing parallels to past major market cycles while debating its potential for future growth alongside other prominent meme-sector assets.

Roku, Inc. engages in the provision of a streaming platform for television. It operates through the following segments: Platform and Devices. The Platform segment includes the sale of digital advertising and distribution of streaming services. The Devices segment is involved in the sale of streaming players, Roku-made televisions, smart home products and services, audio products, and related accessories. The company was founded by Anthony J. Wood in October 2002 and is headquartered in San Jose, CA.

Roku Inc - Ordinary Shares - Class A

Roku Inc

Roku shares are surging following a Bloomberg report that the company is exploring a potential sale and has held preliminary talks with major media companies. Investors are closely watching this development alongside positive momentum from a recent milestone of 100 million active households and anticipation for the upcoming quarterly earnings report.

Litecoin is a decentralized, peer-to-peer digital currency designed to enable instant, near-zero cost payments to individuals and merchants worldwide. As an open-source global payment network that functions independently of central banks or intermediaries, its main value proposition lies in providing a scarce digital asset with a fixed maximum supply of 84 million tokens.  The network operates using a Proof of Work mechanism where computers solve complex puzzles to confirm transactions and secure the blockchain. It is distinguished by a block generation time of 2.5 minutes, which allows for faster transaction confirmations and a higher total throughput than earlier protocols. Key technical features include the Scrypt hashing algorithm, which promotes wider network participation, and MimbleWimble Extension Blocks, which improve user privacy by allowing transaction details to be hidden.  The LTC token is used for settling global payments, executing microtransactions through smaller units called litoshis, and diversifying digital portfolios with a highly liquid asset. New tokens are issued to miners as rewards for verifying blocks, though these rewards undergo a halving event approximately every four years to strictly control inflation. This process ensures the ledger maintains immutability, meaning records cannot be changed once they are saved to the global network.  Created by former Google engineer Charlie Lee, the project is supported by the Litecoin Foundation, a non-profit organization dedicated to ecosystem adoption. Unlike many venture-backed projects, it is maintained by a decentralized community of independent developers and a global network of miners. The project has seen recent institutional adoption, with entities like Lite Strategy and Luxxfolio Holdings adding significant amounts of LTC to their corporate treasuries as of late 2025.

Litecoin

Litecoin is trending as investors debate its long-term potential as a reliable payment-focused digital asset versus its recent price underperformance compared to other crypto coins. The community is intensely focused on technical indicators, potential institutional interest, and the network's resilience as they watch for a breakout from current consolidation levels.

Albemarle Corp. engages in the development, manufacture, and marketing of chemicals for consumer electronics, petroleum refining, utilities, packaging, construction, transportation, pharmaceuticals, crop production, food-safety, and custom chemistry services. It operates through the following segments: Energy Storage, Specialties, and Ketjen. The Energy Storage segment develops and manufactures a broad range of basic lithium compounds, including lithium carbonate, lithium hydroxide, and lithium chloride. The Specialties segment focuses on optimizing a portfolio of bromine and specialized lithium solutions. The Ketjen segment consists of clean fuels technologies, fluidized catalytic cracking catalysts and additives, and performance catalyst solutions, which is primarily composed of organometallics and curatives. The company was founded in 1993 and is headquartered in Charlotte, NC.

Albemarle Corp.

Albemarle Corp

Albemarle is experiencing a strong rally as community sentiment shifts, driven by a rebound in lithium spot prices and increasing demand from utility-scale energy storage projects. Investors are actively discussing the stock's breakout potential as the sector shows signs of recovering from cyclical lows, while attention remains fixed on supply-side constraints and the role of critical minerals in the ongoing electrification of the grid.

Starbucks Corp. engages in the production, marketing, and retailing of specialty coffee. It operates through the following segments: North America, International, and Channel Development. The North America segment focuses on the United States and Canada. The International segment is involved in China, Japan, Asia Pacific, Europe, Middle East, Africa, Latin America, and Caribbean. The Channel Development segment includes roasted whole bean and ground coffees, Seattle’s Best Coffee, and Teavana-branded single-serve products. The company was founded by Jerry Baldwin and Howard D. Schultz on November 4, 1985, and is headquartered in Seattle, WA.

Starbucks Corp.

Starbucks Corp

Starbucks is attracting significant attention as investors analyze the impact of recent cost-cutting measures, leadership changes, and strategic pivots in key international markets like China. Meanwhile, the community is actively debating the stock's long-term growth potential, with retail traders focusing on technical breakout patterns and shifting consumer sentiment toward the brand's premium coffee experience.

Intellia Therapeutics, Inc. is a biopharmaceutical company, which engages in the development of curative therapeutics using the CRISPR/Cas9 system. Its CRISPR/Cas9 system transforms medicine by both producing therapeutics that permanently edit and/or correct disease-associated genes in the human body with a single treatment course and creates engineered cells that can treat oncological and immunological diseases. The company was founded by Andrew May, Luciano Marraffini, Rodolphe Barrangou, Nessan Bermingham, Rachel Haurwitz, Erik Sontheimer, Jennifer Doudna and Derrick Rossi in May 2014 and is headquartered in Cambridge, MA.

Intellia Therapeutics Inc

Intellia Therapeutics is trending following positive Phase 3 results for its hereditary angioedema therapy, despite facing volatility from a recent equity offering. While some investors are concerned about dilution, community sentiment remains heavily focused on the stock's significant short interest, with many anticipating a potential squeeze driven by the company's long-term commercialization prospects.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Ocugen's Gene-Agnostic Eye Therapies Could Reshape Late-Stage Care

OCGN is advancing gene-agnostic eye therapies across retinal diseases, with key trial data and regulatory milestones approaching in 2026 and 2027.

OCGN's Catalyst Calendar for Trial Data and Filings Through 2028

Ocugen's three ocular gene therapy programs could deliver trial data, filings, and potential BLA milestones through 2028 as key readouts approach.

Before Buying Regenxbio Inc (RGNX) Stock, Check Out the Cash Runway

Before Buying Regenxbio Inc (RGNX) Stock, Check Out the Cash Runway...

REGENXBIO to Participate in Upcoming Investor Conferences

REGENXBIO to Participate in Upcoming Investor Conferences REGENXBIO to Participate in Upcoming Investor Conferences PR Newswire ROCKVILLE, Md., May 18, 2026 ROCKVILLE, Md., May 18, 2026 /PRNewswire...

Regenxbio (RGNX) Q1 2026 Earnings Transcript

@media (max-width: 768px) { .image-container { width: 100% !important; float: none !important; margin: 0 0 1rem 0 !important; } } Image source: The Mo...

RGNX Stock On Track For Worst Day Ever As Big Q1 Loss, Cash Concerns Eclipse Duchenne Trial Success  

Equity

REGENXBIO on Thursday reported strong results from its main late-stage trial of RGX-202 for Duchenne muscular dystrophy.


REGENXBIO Advances Duchenne Gene Therapy Toward Accelerated Approval

REGENXBIO reports positive Phase 3 Duchenne trial data as RGX-202 met its primary endpoint with strong safety results.read more...

Regenxbio Shares Rise After Positive Duchenne Trial Results

Regenxbio Shares Rise After Positive Duchenne Trial Results...

Regenxbio (RGNX) Reports Q1 Loss, Lags Revenue Estimates

Regenxbio (RGNX) delivered earnings and revenue surprises of -26.94% and -73.13%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

REGENXBIO Reports First Quarter 2026 Financial Results and Operational Highlights

REGENXBIO Reports First Quarter 2026 Financial Results and Operational Highlights REGENXBIO Reports First Quarter 2026 Financial Results and Operational Highlights PR Newswire ROCKVILLE, Md., May 14...

Current Price	$6.66
Prev Close	$6.28
Open	$6.36
Dividend Yield	0.00%
50-Day Moving Average	$8.05
Beta	1.68
Avg. Volume	2.09M
PE Ratio	-1.19

52-Week High	$16.19
52-Week Low	$5.46
Market Capitalization	$344.31M
EPS (Annual)	-$3.76
Price to Book	16.31
Revenue Per Employee	$459,409.70

RGNXRegenxbio Inc

Fundamentals

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest RGNX News